PolyPeptide Group AG, a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced that its shareholders approved all proposals by the board of directors at an extraordinary general meeting held on October 26, 2026. The approvals mark a significant step toward the completion of a public tender offer by Samsung Peptide AG, a wholly owned subsidiary of Samsung Biologics Co., Ltd., for all publicly held registered shares of PolyPeptide.
Shareholders elected John Chongbo Rim, Seungho Ryu, Cheol Woo Ryu, Mihyun Yang and Joonkyung Seong as members of the Board for a term ending at the conclusion of the next annual general meeting. John Chongbo Rim was elected as chair of the Board, and Cheol Woo Ryu and Seungho Ryu were elected as members of the Remuneration and Nomination Committee. All elections are subject to and effective as of the settlement of the tender offer.
In addition, shareholders resolved, subject to the satisfaction or waiver of all offer conditions set forth in the offer prospectus of Samsung Peptide AG dated 31 August 2026 (other than the condition in section B.7.1(e)), to remove from PolyPeptide’s articles of association the transfer restrictions (Vinkulierung) and the voting limitations (Stimmrechtsbeschränkungen). This removal eliminates a key structural barrier to the takeover and is expected to facilitate the acquisition.
The news matters because it signals the near-completion of Samsung Biologics’ acquisition of PolyPeptide, a company that plays a critical role in the global peptide CDMO market. PolyPeptide serves pharma and biotech customers across pre-pre-clinical to commercial stages, with significant exposure to metabolic diseases, including GLP-1 therapies. The company operates six GMP-certified facilities in Europe, the U.S. and India. The change in control could have broad implications for the peptide supply chain and for customers developing next-generation medicines.
For readers and industry observers, the approval of the new board and the removal of transfer restrictions are the final procedural hurdles before the tender offer can settle. The development underscores the growing strategic interest in peptide manufacturing capabilities, particularly as demand for GLP-1-based treatments continues to rise. Investors and industry stakeholders will now watch for the settlement of the offer and the integration of PolyPeptide into Samsung Biologics’ broader biologics business.
Further details are available in the original release on www.newmediawire.com and in the file PolyPeptide_EGM Results 2026_ENG. For more information about PolyPeptide, visit polypeptide.com.
